Kissei Pharmaceutical
Kissei is a Japanese pharmaceutical company from Matsumoto, founded in 1946, whose in-licensed haematology and oncology products go through the Japanese phase 3 trials it leads.
Overview
Kissei Pharmaceutical Co., Ltd., headquartered in Matsumoto, Nagano, and listed in Tokyo, develops and markets prescription medicines in urology, nephrology and rare diseases, and in-licenses haematology and oncology products for the Japanese market, running the domestic phase 3 trials needed for approval. ClinicalTrials.gov lists Kissei as lead sponsor of phase 3 cancer trials.
Similar pages
not linked directly; found by shared links- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyIntra-IMMUSG
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyLee's Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.